Skip to main content

ARVN

Stock

ARVN

Stock
Health Care
Biotechnology

Performance overview

ARVN Price
Price Chart

Forward-looking statistics

Beta
1.42
Risk
61.24%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Company info

SectorHealth Care
IndustryBiotechnology
Employees425
Market cap$1.8B

Fundamentals

Enterprise value-$406.6M
Revenue$426.9M
Revenue per employee
Profit margin-10.92%
Debt to equity1.59

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.66
Dividend per share
Revenue per share$5.92
Avg trading volume (30 day)$16M
Avg trading volume (10 day)$13M
Put-call ratio

Macro factor sensitivity

Growth+0.3
Credit+7.2
Liquidity+0.7
Inflation-4.6
Commodities-1.6
Interest Rates-2.5

Valuation

Dividend yield0.00%
PEG Ratio-1.71
Price to sales1.36
P/E Ratio-1.71
Enterprise Value to Revenue-0.95
Price to book0.88

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day
Ex. dividend day

News

Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research (June 16, 2025)
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Arvinas, Inc. ARVN unveiled first-in-human data on Friday for its experimental Parkinson's disease treatment, ARV-102.

Benzinga (April 4, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free